Get started
Author

Lucía Villalón

Observed names: L Villalón, L. Villalon, L. Villalón, L.B. Villalón, Lucia Villalon, Lucia Villalón, Lucı́a Villalón, Villalon, Lucia, Villalón, Lucía
Observed institutions: Hospital Universitario Fundación Alcorcón, Hospital Universitario 12 De Octubre, Hospital Rafael Méndez, Hospital General Universitario de Elche, Hospital Universitario Fundación Jiménez Díaz, Hospital Universitario Ramón y Cajal, Instituto de Investigación Sanitaria Fundación Jiménez Díaz
ORCID: 0000-0002-3506-1810
Observed ORCID: 0000-0002-3506-1810
OpenAlex ID: A5030976413
Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach
2006 · R Villuendas, J L Steegmann, et al. · Leukemia · 111
Treatment of Febrile Neutropenia and Prophylaxis in Hematologic Malignancies: A Critical Review and Update
2014 · Paola Villafuerte-Gutierrez, Lucia Villalon, et al. · Advances in Hematology · 83
PDF
SARS‐CoV ‐2‐reactive antibody detection after SARS‐CoV ‐2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group
2021 · José Luis Piñana, Lucia López‐Corral, et al. · American Journal of Hematology · 66
Autologous peripheral blood progenitor cell transplantation with <2×106 CD34+/kg: an analysis of variables concerning mobilisation and engraftment
2000 · Lucía Villalón, Jesús Odriozola, et al. · The Hematology Journal · 45
Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.
2003 · Francisco Cervantes, Juan-Carlos Hernández-Boluda, et al. · PubMed · 42
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
2022 · A. Luna, L. Pérez-Lamas, et al. · Annals of Hematology · 41
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders
2022 · José Luis Piñana, Lucia López-Corral, et al. · Journal of Hematology & Oncology · 38
PDF
Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage
2010 · Pilar Giraldo, Pilar Irún, et al. · Blood Cells Molecules and Diseases · 34
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients
2023 · José Luis Piñana, Lourdes Vazquez, et al. · Blood Cancer Journal · 33
PDF
Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders?
2008 · Dolores Subirá, Patricia Font, et al. · Translational research · 33
SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination
2023 · José Luis Piñana, Rodrigo Martino, et al. · Bone Marrow Transplantation · 32
PDF
Identification of seven novel SMPD1 mutations causing Niemann–Pick disease types A and B
2012 · P Irun, M Mallén, et al. · Clinical Genetics · 32
Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project
2016 · Pilar Giraldo, Marcio Andrade-Campos, et al. · Blood Cells Molecules and Diseases · 30
PDF
Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?
2018 · On behalf of the CML Spanish Group (GELMC), Santiago Osorio, et al. · Annals of Hematology · 29
Management of Persistent SARS-CoV-2 Infection in Patients with Follicular Lymphoma
2021 · Pilar Martínez-Barranco, María García-Roa, et al. · Acta Haematologica · 18
PDF
Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab
2011 · Carlos Vallejo, Eduardo Ríos, et al. · Expert Review of Hematology · 17
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
2022 · Ricardo Sánchez, Sara Dorado, et al. · Scientific Reports · 16
PDF
Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country
2020 · of the GELLC (Grupo Español de Leucemia Linfática Crónica), Ana Muntañola, et al. · Experimental Hematology and Oncology · 15
PDF
Splenic Marginal Zone B-Cell Lymphoma with Epidermotropic Skin Involvement
2012 · E. Gómez-de la Fuente, L.B. Villalón, et al. · Actas Dermo-Sifiliográficas · 14
PDF
Linfoma B esplénico de la zona marginal con afectación cutánea epidermotropa
2011 · E. Gómez-de la Fuente, L.B. Villalón, et al. · Actas Dermo-Sifiliográficas · 13
PDF
Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients
2022 · José Luis Piñana, Pablo Rodríguez-Belenguer, et al. · Annals of Hematology · 11
PDF
Is Veno-occlusive Disease a Specific Syndrome or the Exacerbation of Physiopathologic Hemostatic Changes in Hematopoietic Stem Cell Transplantation (HSCT)?
2000 · Lucı́a Villalón, Angel Garcı́a Avello, et al. · Thrombosis Research · 10
Imatinib mesylate (STI571) treatment in patients with chronic‐phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation
2003 · Francisco Cervantes, Juan‐Carlos Hernández‐Boluda, et al. · British Journal of Haematology · 9
Cryopreserving with increased cellular concentrations of peripheral blood progenitor cells: clinical results.
2002 · L Villalón, J Odriozola, et al. · PubMed · 7
Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain
2023 · Anna Torrent, Mireia Morgades, et al. · European Journal Of Haematology · 6
PDF
Works count: 59
Citation count: 806
H-index: 16
I10-index: 22
Year
Topic
Type